ETV6-PDGFRB results from the t(5;12)(q31-33;p13) and, although rare, is the most frequent of at least 15 known PDGFRB fusion genes. ETV6-PDGFRB is usually seen in patients with chronic myelomonocytic leukaemia, atypical chronic myeloid leukaemia (aCML) or chronic eosinophilic leukaemia (CEL), with most patients exhibiting peripheral blood or bone marrow eosinophilia. Although ETV6-PDGFRB disease may be controlled with conventional therapy (hydroxyurea, busulphan, interferon-a), many die from transformed disease or other causes. More recently, however, imatinib has emerged as the standard therapy for PDGFR-rearranged patients, with most experiencing sustained haematologic and cytogenetic remission, and many achieving molecular remission. 1 Molecular confirmation of a PDGFR rearrangement is therefore important for appropriate clinical management and monitoring response to therapy. For the t(5;12)(q31-33;p13), confirmation of the presence of ETV6-PDGFRB is particularly important since many cases with this translocation have a distinct molecular aetiology, with upregulation of IL-3 expression and no involvement of PDGFRB.
2
In the great majority of positive cases, ETV6 exon 4 splices to PDGFRB exon 11 and is typically detected by reverse transcription PCR (RT-PCR) using primers directed to ETV6 exon 3 or 4 and PDGFRB exon 11. Out of 10 positive cases we have detected with these primer combinations, only one had a variant fusion in which ETV6 exon 4 was fused to PDGFRB exon 9 (unpublished data). Recently, a patient with idiopathic myelofibrosis and an ETV6 exon 7-PDGFRB exon 10 fusion was reported and it was suggested that this novel transcript may have accounted for the somewhat unusual clinical phenotype seen in this case. 3 Importantly, both these variants are detectable using the standard primer sets above. Here we report a novel ETV6-PDGFRB fusion with breakpoints outside this region.
A 19-year-old male (E1026) presented to the outpatient department with a 2-month history of fever. On examination he was found to have generalized lymphadenopathy, hepatosplenomegaly and bony swellings over the left clavicle and right tibia. There were no bleeding manifestations. A peripheral blood smear showed a total leucocyte count exceeding 100 Â 10 9 /l with a left shift. The bone marrow aspirate was suggestive of a myeloproliferative disorder with an increase in the number of basophils and eosinophils. Fine needle aspiration of the lymph node showed infiltration by blasts which cytochemistry revealed to be negative for myeloperoxidase and periodic acid schiff. Flow cytometry of the peripheral blood and lymph node aspirate was positive for myeloid markers (CD 11c, 13, 15 and 33) along with CD45 and myeloperoxidase. BCR-ABL was not detected by RT-PCR and cytogenetics showed a t(5;12)(q31-33;p13). A diagnosis of atypical CML in blast crisis was made. Despite the fact that ETV6-PDGFRB was not detected by RT-PCR, he was started on imatinib mesylate (300 mg twice a day) after taking informed consent. The patient had a complete haematological and cytogenetic response (including complete regression of the lymph nodes, bony swellings and hepatosplenomegaly) at 3 months post-treatment. He continues in remission on 600 mg/ day imatinib, 1 year after diagnosis.
In view of the excellent response to imatinib, we performed further analysis to determine if PDGFRB was involved (material was not available for molecular cytogenetic analysis). We have previously reported a simple multiplex RT-PCR assay to identify PDGFRA fusions by looking for overexpression of sequence encoding the kinase domain (which is retained in any fusion) relative to that encoding the extracellular domain (which is expressed only by the normal, unrearranged gene). 4 Attempts to establish a similar assay for PDGFRB were only partially successful and therefore we developed an analogous strategy using multiplex ligation-dependent probe amplification (MLPA). We designed probes targeting the region encoding the kinase domain and upstream sequences of PDGFRA, PDGFRB and FGFR1. MLPA was performed on patient and control cDNA essentially as described. 5 The cDNA MLPA assay detected relative overexpression of the PDGFRB kinase domain in 9 of 9 patients known to harbour PDGFRB fusion genes but not in 16 normal controls. Overexpression of the kinase domain was also seen for E1026, suggesting the presence of a PDGFRB fusion (Figure 1a) . 
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Figure 2
Sequence of ETV6-PDGFRB fusions described to date, with the most common variant at the top and the fusion in case E1026 at the bottom.
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We used 5 0 rapid amplification of cDNA ends PCR (Invitrogen, Paisley, UK) to characterize the fusion, employing reverse primers derived from sequences located downstream of known PDGFRB breakpoint locations. The resulting PCR products were cloned and sequencing revealed an in-frame mRNA fusion between full-length ETV6 exon 7, 34 bp derived from ETV6 intron 7 and a truncated PDGFRB exon 12 (Figures 1b and 2) . The presence of the fusion was confirmed by RT-PCR and by amplifying and sequencing fusion point from genomic DNA (not shown).
The PDGFRB sequence retained in the novel fusion is downstream of the PCR primer we had initially used, explaining why ETV6-PDGFRB was not detected. To determine if we might have missed other similar cases, we analyzed 10 cases with a t(5;12) who tested negative for ETV6-PDGFRB using primers ETV6.Ex2F (5 0 -TCAGGATGGAGGAAGACTCG-3 0 ) and PDGFRB.Ex14R (5 0 -CCCCAACAGGTTGACCACGTTCAG-3 0 ). All were negative, indicating that this variant is not common, but nevertheless we now routinely use these primers to screen t(5;12) cases.
This unusual fusion in our case is reminiscent of that seen for FIP1L1-PDGFRA, for which breaks almost always fall within PDGFRA exon 12 and FIP1L1 intron-derived sequence is frequently incorporated into the mature mRNA. 6 As a consequence, the PDGFRa autoinhibitory WW-like domain is disrupted resulting in partner protein-independent activation of the kinase moiety. 7 The disruption of PDGFRb WW-like domain in our case is unexpected in view of the fact that ETV6 encodes a dimerization domain that is required for transformation by 'normal' ETV6-PDGFRB.
It is notable that our case presented with advanced phase disease. The fusion retained ETV6 exons 1-7, in common with that described by Tokita et al. 3 in a case that also presented with advanced features. In contrast to the most common fusion involving ETV6 exons 1-4, these variants are predicted to encode a chimaeric protein that retains the ETV6 internal and ETS DNA-binding domains. It is possible that retention of these domains leads to a more aggressive phenotype; however, it would be premature to draw any clear conclusions from just two cases. It is noteworthy, however, that our case responded well to imatinib despite being treated in advanced phase. Good responses to imatinib have been described for FIP1L1-PDGFRA-associated CEL in transformation 8 and this may be a general feature of diseases associated with PDGFR fusions.
In summary, it appears that breakpoint diversity for the ETV6-PDGFRB fusion is more common than originally reported.
Screens for this fusion should employ primers capable of detecting all variants in order to provide an accurate molecular diagnosis and appropriate clinical management.
Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab We read with interest the article by Karlsson et al. 1 in Leukemia (2007), which reports five patients treated successfully with alemtuzumab (anti-CD52) for refractory autoimmune hemolytic anemia (AIHA) complicating B-cell chronic lymphocytic leukemia (B-CLL). AIHA occurs in about 5% of patients with B-CLL and requires treatment including corticosteroids, cytotoxic drugs, splenectomy or immunosuppressive drugs. 2 Recently, rituximab (anti-CD20) has been used with efficacy in AHAI complicating B-CLL. 3 But relapses are frequent and some patients become refractory.
We report the case of a 69-year-old woman who presented B-CLL complicated by AIHA. B-CLL was diagnosed in 1994 and was treated with different chemotherapy regimens (chlorambucile, cyclophosphamide and then fludarabine) between 1994 and 2002. In October 2003 chlorambucile was introduced for progressing B-CLL; the direct antiglobulin test (DAT) was
